CN Patent

CN115776882A — 长效配制品

Assigned to Janssen Pharmaceutica NV · Expires 2023-03-10 · 3y expired

What this patent protects

本发明涉及用于经由肌内或皮下注射施用的药物组合物，这些药物组合物包含悬浮在药学上可接受的水性载体中的微米或纳米颗粒的抗‑TB化合物贝达喹啉并且包含作为表面改性剂的泊洛沙姆；还涉及此类药物组合物在治疗和预防病原性分枝杆菌感染中的用途。

USPTO Abstract

本发明涉及用于经由肌内或皮下注射施用的药物组合物，这些药物组合物包含悬浮在药学上可接受的水性载体中的微米或纳米颗粒的抗‑TB化合物贝达喹啉并且包含作为表面改性剂的泊洛沙姆；还涉及此类药物组合物在治疗和预防病原性分枝杆菌感染中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN115776882A
Jurisdiction
CN
Classification
—
Expires
2023-03-10
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.